Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12413300 | 0.82 | CYP2A6 (0.36) | ESR1ESR2HDAC3HDAC4HDAC1 | |
| SCHEMBL12413292 | 0.79 | ESR1 (0.40) | ESR1ESR2RAB9A | |
| SCHEMBL12413294 | 0.76 | NPC1 (0.31) | MAPT | |
| SCHEMBL12503562 | 0.75 | ESR1 (0.31) | ESR1ESR2 | |
| SCHEMBL12413194 | 0.73 | BCL2L1 (0.38) | ESR1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12413307 | 0.71 | BCL2L1 (0.36) | ESR1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12413208 | 0.70 | BCL2L1 (0.38) | ESR1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL9977515 | 0.69 | ESR1 (0.61) | ESR1ESR2HDAC3HDAC4HDAC1 | |
| SCHEMBL12413275 | 0.69 | PKM (0.39) | — | |
| SCHEMBL12413366 | 0.69 | BCL2L1 (0.35) | ESR1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166362-A1 | NOVEL COMPOUND AND ORGANIC SEMICONDUCTOR MATERIAL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166362-A1 | NOVEL COMPOUND AND ORGANIC SEMICONDUCTOR MATERIAL | SCLY, MSRB3, SOD1 | ESR1 425/4885ESR2 75/4885HDAC3 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.